Today: 18 November 2025
Subscribe
Browse Category

Healthcare Innovation News 16 October 2025 - 18 November 2025

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Published: November 18, 2025 Medtronic plc (NYSE: MDT) is back in the spotlight today after reporting stronger‑than‑expected results for the second quarter of fiscal 2026 and raising its full‑year outlook. The medical technology giant delivered solid revenue and earnings growth, highlighted powerful momentum in its cardiac ablation franchise, and signaled confidence in accelerating growth in the second half of the year. Medtronic News+1 Shares of Medtronic jumped intraday to around $100–101, up roughly 4–5% after the announcement, as investors reacted to a classic “beat‑and‑raise” quarter. ChartMill Q2 FY26 by the numbers: solid beat on revenue and EPS For the quarter
18 November 2025
 ·  ·  ·  ·  · 
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck & Co. (NYSE: MRK) has agreed to acquire Cidara Therapeutics (Nasdaq: CDTX) in a deal valued at about $9.2 billion, a blockbuster move that gives the pharma giant a late‑stage, long‑acting influenza prevention drug as it prepares for life after cancer juggernaut Keytruda. Reuters+1 Key points at a glance Deal terms: a rich premium for a single late‑stage asset Under the definitive agreement announced this morning, Merck will, through a subsidiary, launch a tender offer to purchase all outstanding shares of Cidara for $221.50 per share in cash. That price represents a 108.9% premium to Cidara’s last closing price
14 November 2025
 ·  ·  ·  ·  ·  · 
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health, Inc. (NYSE: OSCR) announced new individual-market plans for South Florida ahead of the 2026 Open Enrollment window and spotlighted HelloMeno, a menopause-focused offering it and partner Elektra Health describe as the first plan of its kind in the individual market. The rollout lands as Washington headlines around ACA premium tax credits pressure managed-care shares broadly; investors are watching OSCR’s intraday action closely. Business Wire+2PR Newswire+2 Key takeaways What Oscar announced today Oscar said it will offer new, affordable individual‑market plans across South Florida for plan year 2026, with options available in Miami‑Dade, Broward, Palm Beach, Martin, and St.
10 November 2025
 ·  ·  ·  ·  · 
Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Company Overview: Telehealth for High-Acuity Care VSee Health, Inc. is a Silicon Valley-founded telehealth technology and services provider specializing in high-acuity virtual care. Founded in 2008 by Dr. Milton Chen, VSee built a secure video telemedicine platform so robust it was even utilized by NASA for astronaut healthcare businesswire.com. Today, after merging with iDoc Telehealth via a SPAC deal in mid-2024, VSee offers an integrated suite of telehealth solutions for hospitals and health systems. The company’s headquarters are in Massachusetts, and it has ~154 employees as of 2025 finviz.com. Business Model: VSee’s platform combines telehealth software with physician services to
4 November 2025
 ·  ·  ·  ·  · 
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Analyst outlook & forecast: Long-term, analysts model robust growth. For example, one financial model projects ~18% revenue CAGR: ~$3.3 billion in sales by 2028 and ~$261 million net income simplywall.st. Another estimate sees revenue rising from ~$2.35 B in 2025 to ~$3.34 B by 2027 tipranks.com, and free cash flow turning positive in 2025 simplywall.st. These forecasts assume continued momentum in weight-loss/metabolic services plus gains in new verticals. Yet many investors note the high valuation (HIMS trades near ~$45 with market cap in the billions) and regulatory/legal risks. Community “fair value” estimates vary widely (some as low as $41) due to uncertainty simplywall.st. Key
3 November 2025
 ·  ·  ·  ·  · 
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Company Overview and Background Acrivon Therapeutics is a Boston-area biotech (NASDAQ: ACRV) founded in 2018, emerging with a mission to revolutionize cancer treatment through precision medicine stockanalysis.com. The company’s name “Acrivon” is derived from “accurate” or “precision,” reflecting its core approach: develop targeted oncology drugs hand-in-hand with diagnostics that pinpoint the patients who will respond. Acrivon’s proprietary platform, AP3 (Acrivon Predictive Precision Proteomics), lies at the heart of this strategy. Using proteomics and AI tools, AP3 measures the activity of myriad proteins and signaling pathways inside tumor cells in their native state, rather than just analyzing DNA mutations globenewswire.com globenewswire.com.
3 November 2025
 ·  ·  ·  ·  · 
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Stock Price and Recent Performance RANI has seen explosive moves this month. As of the Oct 31 close, Rani Therapeutics stock was $2.20 (up $0.75, +51.7%) stockanalysis.com. This follows a monumental rally: on Oct 17, RANI nearly tripled from ~$0.47 to an intraday high of $2.39 (+248%) ts2.tech stockanalysis.com after the company announced the Chugai collaboration and financing. Even after that spike, RANI remained volatile – it spent mid-October around $1.50–2.50, briefly crossing Nasdaq’s $1 bid threshold and greatly lifting its market cap. Volume has been extremely high: for example, ~172 million shares traded on Oct 20 and ~124 million on Oct 21 stockanalysis.com, versus
31 October 2025
 ·  ·  ·  ·  · 
From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

Market Analysis & Forecast: For now, analysts and investors appear in “wait and see” mode. Near-term catalysts will be pivotal. These include the finalization (or not) of the Antalpha $250M convertible deal – which would inject capital but on what terms? – and the company’s next earnings report (to show if core healthcare revenue is growing or still minuscule). If Bitcoin’s price continues to climb in late 2025, it could boost KindlyMD’s asset value and perhaps its stock; conversely, a crypto downturn or interest rate spike could hurt both the value of its BTC and its ability to raise funds
28 October 2025
 ·  ·  ·  · 
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Sources: CPHI Frankfurt event coverage contractpharma.com gxpnews.net; GxP News gxpnews.net gxpnews.net; The Medicine Maker/Conexiant conexiant.com conexiant.com; GlobeNewswire (Hengdian/Apeloa) globenewswire.com; Evaluate Pharma forecast evaluate.com evaluate.com; Reuters reuters.com; TechStock² / TS2 Tech ts2.tech ts2.tech; TS2 Tech ts2.tech ts2.tech.
28 October 2025
 ·  ·  ·  · 
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

Clinical and Pipeline Progress CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency (AATD). The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO
19 October 2025
 ·  ·  ·  ·  · 
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” news.samsung.com. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic adults. Recently, two developments have driven the stock: Samsung’s strategic deal (announced Oct. 16) and positive trial data (released at ESMO). These moves suggest GRAIL is gaining traction, but they also highlight the challenges ahead in turning cutting-edge science into
18 October 2025
 ·  ·  ·  ·  · 
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys’ stock surge on Oct. 16 mirrors growing investor interest in its reproductive healthcare pipeline. The company’s FemaSeed™ technology is designed to boost pregnancy rates by delivering sperm directly into the fallopian tube, and published trials report more than double the pregnancy rate of traditional intrauterine insemination globenewswire.com stocktitan.net. Femasys is positioning FemaSeed as a first-line, lower-cost infertility option ahead of IVF. Meanwhile, FemBloc offers a first-of-its-kind permanent birth control that creates a natural scar in the fallopian tubes, avoiding surgery ir.femasys.com ir.femasys.com. This week’s ASRM announcement – coinciding with broader fertility news – helped lift FEMY. Also on Oct. 16, national media reported an expected
16 October 2025
 ·  ·  ·  ·  · 
1 2
Go toTop